Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

APVOVery BullishResearch Analysisnews

High materiality9/10

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:59 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The impressive clinical trial results significantly boost APVO's market position, reminiscent of prior biotech surges from exceptional trial outcomes.

AI summary

What happened, with direct paths to the underlying reporting

APVO stock surged 137.2% with high trading volume. New data from RAINIER trial shows 85% remission in AML patients. No CRS observed; mipletamig demonstrates strong safety profile. Direct offering of $8 million at $3.25 per share announced. Unique immunotherapy approach positions APVO favorably in AML market.

APVO stock surged 137.2% with high trading volume.
New data from RAINIER trial shows 85% remission in AML patients.
No CRS observed; mipletamig demonstrates strong safety profile.
Direct offering of $8 million at $3.25 per share announced.
Unique immunotherapy approach positions APVO favorably in AML market.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session